Clal Biotechnology | CBI - Current Liabilities


Clal Biotechnology reported ILS6.66M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Arca Biopharma USD 20.97M 8.86M Sep/2025
aTyr Pharma USD 15.68M 148K Sep/2025
Bio Path USD 7.86M 3.12M Jun/2025
Brainstorm Cell Therapeutics USD 9.02M 495K Sep/2025
Cara Therapeutics USD 10.68M 9.48M Jun/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 20.28M 300K Sep/2025
Immunic USD 30.08M 2.77M Sep/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.29M 381K Dec/2025
RedHill Biopharma USD 22.29M 64K Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024